Navigation Links
Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Date:7/16/2009

cquisitions; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this press release to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended March 31, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
2. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
3. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
4. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
5. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
6. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
7. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
8. Angiotech announces date of annual general meeting of shareholders
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
10. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
11. Angiotech announces positive results from Bio-Seal(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014 DuPont Pioneer announced ... as vice president of Agricultural Biotechnology (ABT), effective July ... he served most recently as president, chief executive officer ... business leadership in the seed and crop protection industry ... Paul E. Schickler , president of DuPont Pioneer. “I ...
(Date:7/23/2014)... , July 23, 2014  Sofinnova Ventures, a ... announced the closing of Sofinnova Venture Partners IX, L.P. ... excess of the initial fund target of $425 million. ... successful biotechnology companies. Consistent with recent funds, SVP IX ... stage clinical programs, along with select investments in earlier ...
(Date:7/23/2014)... Adult stem cells that are required ... not magical. However, many current regenerative medicine ... if they were magical. , Many current clinical ... “stem cell tourism,” are evaluating heterologous tissue stem ... regenerative medicine therapies. In reality, these are not ...
(Date:7/22/2014)... of Standards and Technology (NIST) and California Institute ... for an atomic clock that is based on ... The microcomb clock, featured on the cover of ... Optica ,* is the first demonstration of all-optical ... of optical frequencies to lower microwave frequencies. (Optical ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5'Comb on a chip' powers new NIST/Caltech atomic clock design 2
... work showing how nanowires carved in impurity-laden diamond ... developed a scalable manufacturing process to craft arrays ... photon control. The development supports efforts to ... stage for diamond-based microchips. Additionally, the technology ...
... 2011 Applied Precision is proud to announce ... super-resolution microscopy system at McGill University in Montreal, ... is a super-resolution microscope utilizing proven three-dimensional structured ... in volume resolution and outstanding widefield imaging capabilities. ...
... Ohio, Oct. 18, 2011 Minimally Invasive Devices, Inc ... new product, FloShield PLUS , utilizing the novel Flo-X ... of the end of the laparoscope without removal from the ... MID,s FloShield laparoscopic visualization system. In the first 19 FloShield ...
Cached Biology Technology:Diamonds, silver and the quest for single photons 2Diamonds, silver and the quest for single photons 3Applied Precision Announces the 25th Installation of Its DeltaVision OMX Super-Resolution Microscope at McGill University 2
(Date:7/23/2014)... Tracking of blue whales by satellite over a 15-year ... whales consistently return to feed in specific locations each ... in the open-access journal PLOS ONE by ... data may be used to mitigate human threats to ... has been slow to recover since the establishment of ...
(Date:7/23/2014)... cystic fibrosis patients, scientists at the UNC School of ... that a new CF drug counteracts the intended beneficial ... published today in the journal Science Translational Medicine ... and loses its ability to function properly when in ... several insights into how novel CF pharmacotherapies could be ...
(Date:7/23/2014)... , , , , , ... , , , , ... diseases and extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... several proteins in mice that might act as biomarkers ... step to finding a more reliable way to detect ... teenagers use illegally to boost muscle and reduce fat. ... San Francisco today, scientists John Kopchick and Juan Ding ...
... the White House must be enhanced so that the ... nationfrom energy and the environment, to national security, and ... collaborate internationally. The report,s primary recommendations are that: ... respected leader to be Assistant for Science and Technology ...
... 2008 Mary Tyler Moore, the Juvenile Diabetes Research ... M.D., presented the sixth annual "Excellence in Clinical Research ... annual conference today in Washington, DC. The recipients ... director of the JDRF Gene Therapy Center for Diabetes ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2White House science office needs upgrade 2White House science office needs upgrade 3Florida researchers receive JDRF 'Excellence in Clinical Research Award' 2